ELISA – Products

A new study has shown graphene-based biosensors could play a major role in detecting Interleukin-10 (IL-10), an important inflammation regulator, at significantly lower levels than previous point-of-care measurements.

Sino Biological provides the most cost-effective solution for the rapid production of a large number of antibodies. In response to the rapidly increasing therapeutic needs, Sino Biological combines its expertise in gene synthesis, vector design and transient antibody expression technology to produce highly efficient antibodies in HEK293 and CHO cells in as fast as 2 weeks.

The PrismA ELISA kit is an enzyme-linked immunosorbent assay designed to measure residual ligand leakage when using MabSelect PrismA™ chromatography resin and Fibro™ PrismA chromatography adsorbers. PrismA ELISA kit is the only commercial kit specifically designed for use with MabSelect PrismA™ resins and Fibro™ PrismA adsorbers.

Bioassays, such as the enzyme-linked bioabsorbant assay (ELISA), are standard techniques that require enzyme or fluorescent labels for the detection of target analytes. While these label-based studies give important information about a sample, such as binding affinity, they can only measure the interaction of an analyte at a given concentration and time, and are unable to gather kinetic analysis.

PerkinElmer’s Oxford Immunotec has announced the U.S. Food and Drug Administration has approved the use of the T-Cell Select™ reagent kit for the automation of its T-SPOT®.TB test workflow for in vitro diagnostic use by certified laboratories.

In quantifying therapeutic peptides and proteins in biological matrices, traditional ELISA-only based techniques can suffer from high variability, narrow dynamic range, problems with selectivity and typically cannot use internal standards.

The Signum™ range of surface-active polystyrene microplates from Porvair Sciences set a new high standard for reproducible binding of hydrophobic and hydrophilic proteins.

Beckman Coulter Life Sciences announces it has acquired ValitaCell Ltd, a biotechnology company that creates analytical products and technologies for the biopharmaceutical industry.

Bio-Rad Laboratories, Inc. has introduced a range of type 1 antibodies that inhibit the binding of evolocumab to its target, human proprotein convertase subtilisin/kexin type 9, a protein that has been shown to play a key role in the regulation of cholesterol levels.

Jackson ImmunoResearch announces a new addition to its range of products for scientists developing immunoassays for the serology and diagnostics markets.